BioWorld

Nov. 2, 2009

Novartis Passes on Idenix Lead HCV Antiviral Drug

Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today) Read More

House Health Care Bill Could be Problematic for Drugmakers

Biotech Dollars Continue Flowing with Innovation Getting Its Share

Findings May Impact How the Other Half Lives with Hepatitis

HCV Vaccines, TLRs Advance Away from Protease Spotlight

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...